Editorials
All That Glitters Is Not Gold — Standardizing Diagnosis in Rheumatoid Arthritis Studies
K.P. Liao, V. Bykerk 1223

Who’s Holding up the Queue? Delay in Treatment of Rheumatoid Arthritis
J.E. Homik 1225

Rehabilitation for Ankylosing Spondylitis in the Era of Biologics: Any Room Left for This Treatment?
E. Lubrano, S. D’Angelo, A. Spadaro, C. Palazzi, I. Olivieri 1228

Should Clinicians Start Measuring Flow Mediated Dilation Response in Patients with Systemic Lupus Erythematosus?
C.S. Lau 1231

Review
Challenges in Diagnosing Latent TB Infection in Patients Treated with TNF Antagonists
E.C. Keystone, K.A. Papp, W. Wobeser 1234

Articles
Lymphotixin-α 252 A>G Polymorphism: A Link Between Disease Susceptibility and Dyslipidemia in RA?

Diagnostic Accuracy of ACR/EULAR 2010 Criteria for RA in a 2-Year Cohort
S. Varache, D. Cornec, J. Morvan, et al 1250

Incidence and Risk Factors for Serious Infection in Patients with RA Treated with TNF Inhibitors: A Report from the Registry of Japanese RA Patients for Longterm Safety
Y. Komano, M. Tanaka, T. Nanki, et al, for the REAL Study Group 1258

A Comparison Between IgG- and IgA-class Antibodies to CCP and to Modified Citrullinated Vimentin in Early RA and Very Early Arthritis
A. Svärd, A. Kastbom, M.K. Söderlin, A. Reckner-Olsson, T. Skogh 1265

Persistence with Anti-TNF Therapies in Patients with RA: Observations from the RADIUS Registry
J.A. Markenson, A. Gibofsky, W.R. Palmer, et al 1273

Time to Treatment for New Patients with RA in a Major Metropolitan City
S. Jamal, S.M.H. Alibhai, E.M. Badley, C. Bombardier 1282

Prognostic Indicators of Hospitalized Patients with SLE: A Large Retrospective Multicenter Study in China
X. Feng, Y. Zou, W. Pan, et al 1289

Endothelium-dependent But Not Endothelium-independent Flow-mediated Dilation Is Significantly Reduced in Patients with SLE without Vascular Events: A Metaanalysis and Metaregression
A. Mak, Y. Liu, R.C-M Ho 1296

Longterm Followup After Tapering MMF During Maintenance Treatment for Proliferative Lupus Nephritis
K. Laskari, A.G. Tzioufas, A. Antoniou, H.M. Moutsopoulos 1304

Quantitative Data for Care of Patients with SLE in Usual Clinical Settings: A Patient Multidimensional HAQ and Physician Estimate of Noninflammatory Symptoms
A.D. Askarane, I. Castrejón, T. Pincus 1309

Late-age Onset SSc
R.L. Manno, F.M. Wigley, A.C. Gelber, L.K. Hummers 1317

Expert Agreement on EULAR/EUSTAR Recommendations for the Management of SSc
K.M. Walker, J. Pope, on behalf of the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research Group 1326

Malignancies in Italian Patients with SSc Positive for Anti-RNA Polymerase III Antibodies
S. Varache, D. Cornec, J. Morvan, et al 1329

Rehabilitation Treatment in Patients with AS Stabilized with TNF Inhibitor Therapy. A Randomized Controlled Trial
S. Masiero, L. Bonaldo, M. Pigatto, A. Lo Nigro, R. Ramonda, L. Punzi 1335

The SPARCC Registry for SpA

Resolution of Inflammation Following Treatment of AS Is Associated with New Bone Formation
S.J. Pedersen, P. Chiowchanwisawakit, R.G.W. Lambert, M. Østergaard, W.P. Maksymowycz 1349

Effectiveness and Safety of Etanercept in Patients with PsA in a Canadian Clinical Practice Setting: The REPArE Trial

High Prevalence of Subclinical Left Ventricular Dysfunction in Patients with PsA

Prevalence of Thyroid Autoimmunity in Patients with SpA

Candidate Genes in Patients with Autoinflammatory Syndrome Resembling TNF Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene
S. Borghini, M. Fiore, M. Di Duca, et al 1378
Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors D.S. Goldfarb, P.A. MacDonald, B. Hunt, L. Gunawardhana 1385
Longterm Therapeutic Response to Milnacipran Treatment for FM: A European 1-Year Extension Study Following a 3-Month Study J.C. Branco, P. Cherin, A. Montagne, A. Bouroubi, on behalf of the Multinational Coordinator Study Group 1403

Pediatric Rheumatology

Heterotopic Ossification of the TMJ in JIA S. Ringold, M. Thapa, E.A. Shaw, C.A. Wallace 1423
MLB Expression Genotype in Pediatric-onset SLE: Associations with Susceptibility to Renal Disease and Protection Against Infections Y-C. Tsai, K-W. Yeh, T-C. Yao, Y-L. Huang, M-L. Ku, J-L. Huang 1429
Safety and Efficacy of Rituximab in Severe Juvenile DM: Results from 9 Patients from the French Autoimmunity and Rituximab Registry B. Bader-Meunier, H. Decaluwe, C. Barnerias, et al. for the Club Rhumatismes et Inflammation 1436
Development of IBD in Patients with JIA Treated with Etanercept T.D. van Dijken, S.J. Vastert, V.M. Gerloni, et al. 1436

Images in Rheumatology

Fluorescence Optical Imaging of Juvenile Arthritis S.G. Werner, H-E. Langer, G. Hornreff 1447
OMERACT 10 10th International Consensus Conference on Outcome Measures in Rheumatology Kota Kinabalu, Borneo - May 4-8, 2010 Introduction 1448
Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities N. Dalbeth, F.M. McQueen, J.A. Singh, et al. 1458
Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology? L.K. Stamp, P.P. Khanna, N. Dalbeth, et al. 1462

Toward Development of a FM Responder Index and Disease Activity Score: OMERACT Module Update P.J. Mease, D.J. Clauw, R. Christensen, et al. and the OMERACT Fibromyalgia Working Group 1487
Development of a Disease Severity and Responder Index for PsA — Report of the OMERACT 10 PsA SIG L.C. Coates, A. Mumtaz, P.S. Helliwell, et al. 1496
Endorsement of Definitions of Disease Activity States and Improvement Scores for the AS Disease Activity Score: Results from OMERACT 10 P.M.M.C. Machado, R.B.M. Landewé, D.M. van der Heijde 1502
Developing Disease Activity and Response Criteria in CTD-related ILD L.A. Saketkoo, E.L. Matteson, K.K. Brown, J.R. Seibold, V. Strand; for the Connective Tissue Disease-related Interstitial Lung Disease Special Interest Group 1514

Correspondence

Where in the World is Oral Triamcinolone? L. Roger 1519
Reply R. Aiten 1519
Lupus Related Longitudinal Myelitis D.M. Wingeruch, B.G. Weismanker 1520
Reply P. Zotos 1520
Who Discovered the ESR? A. Grzybowski, J.J. Sak 1521
Reply E.L. Matteson, C.S. Crowson 1523

Letters

Acute Presentation of Tophaceous Myelopathy E. Levin, K. Hurth, R. Joshi, R. Brasington 1525
AS Refractory to TNF Blockade Responds to Tocilizumab J-D. Cohen, R. Ferreira, C. Jorgensen 1527
Primary Aldosteronism Simulating Polymyositis Y-C. Tang, S-K. Wang, W-L. Yuan 1529

Correction

Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial J.A. Singh, M.L. Mahowald, S. Noorbaloochi 1534
Meetings in Rheumatology